Oncologic outcome and safety profile of first-line enfortumab vedotin plus pembrolizumab vs. conventional chemotherapy in advanced urothelial cancer.
- DOI
- 10.37349/etat.2026.1002379
- Published
- 2026
- Container
- Exploration of targeted anti-tumor therapy
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
uncertain Score 53/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- supportingDirectory of Open Access Journals: A matching record was returned by DOAJ.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.37349/etat.2026.1002379,
title = {Oncologic outcome and safety profile of first-line enfortumab vedotin plus pembrolizumab vs. conventional chemotherapy in advanced urothelial cancer.},
author = {Miyake M and Nishimura N and Oda Y and Shimizu T and Inoue T and Anai S and Sakamoto K and Matsumura Y and Toyoshima Y and Ichii D and Iida K and Iwamoto T and Takamatsu N and Tomioka A and Yamamoto H and Maesaka F and Fujimoto K and Nara Urological Research Treatment Group},
year = {2026},
journal = {Exploration of targeted anti-tumor therapy},
doi = {10.37349/etat.2026.1002379},
url = {https://doi.org/10.37349/etat.2026.1002379}
}RIS
TY - JOUR TI - Oncologic outcome and safety profile of first-line enfortumab vedotin plus pembrolizumab vs. conventional chemotherapy in advanced urothelial cancer. AU - Miyake M AU - Nishimura N AU - Oda Y AU - Shimizu T AU - Inoue T AU - Anai S AU - Sakamoto K AU - Matsumura Y AU - Toyoshima Y AU - Ichii D AU - Iida K AU - Iwamoto T AU - Takamatsu N AU - Tomioka A AU - Yamamoto H AU - Maesaka F AU - Fujimoto K AU - Nara Urological Research Treatment Group PY - 2026 JO - Exploration of targeted anti-tumor therapy DO - 10.37349/etat.2026.1002379 UR - https://doi.org/10.37349/etat.2026.1002379 ER -
APA
M, M., N, N., Y, O., T, S., T, I., S, A., K, S., Y, M., Y, T., D, I., K, I., T, I., N, T., A, T., H, Y., F, M., K, F., & Group, N. U. R. T. (2026). Oncologic outcome and safety profile of first-line enfortumab vedotin plus pembrolizumab vs. conventional chemotherapy in advanced urothelial cancer.. Exploration of targeted anti-tumor therapy. https://doi.org/10.37349/etat.2026.1002379
Source records
- pubmed · retrieved 2026-09-25T20:58:40.312Z
- europe-pmc · retrieved 2026-09-25T20:58:40.316Z
- doaj · retrieved 2026-09-25T20:58:40.339Z